Kiniksa Pharmaceuticals International (KNSA) FY 2025 Conference September 04, 2025 09:30 AM ET Company ParticipantsDan Kim - VP - Biotechnology Equity ResearchSanj Patel - CEO & Chairman of BoardRoss Moat - EVP & Chief Commercial OfficerJohn Paolini - EVP & Chief Medical OfficerDan KimHow long is it? Thirty five.Sanj PatelThirty five minutes?Dan KimYes. Oh, welcome. All right. I think we'll get started. Welcome, everyone.I'm Dan Kim with the Wells Fargo BioNTech Research team, and really happy to be here wi ...

Financial Data and Key Metrics Changes - The company reported Q2 revenue of $156.8 million and raised its full-year 2025 revenue guidance to between $625 million and $640 million, up from a previous estimate of $590 million to $600 million [4][5][11]. Business Line Data and Key Metrics Changes - The company has achieved approximately 15% penetration into its target patient population for Arclis, which is focused on recurrent pericarditis, indicating significant room for growth [5][11][34]. - The average treatment duration for Arclis is reported to be 30 months, with 45% of patients who stop therapy restarting within eight weeks due to symptom recurrence [26][27]. Market Data and Key Metrics Changes - The prescriber base for Arclis has expanded significantly, with over 3,475 prescribers by the end of Q2, reflecting a strong educational push and increased awareness of recurrent pericarditis [15][19]. - The company noted that patients often receive multiple misdiagnoses before being correctly identified as having recurrent pericarditis, highlighting the need for better education and awareness in the healthcare system [18]. Company Strategy and Development Direction - The company is focused on value creation and expanding its market presence, particularly for Arclis, which has only begun to penetrate the market [4][5]. - The development pipeline includes KPL-387, a potential monthly liquid formulation for recurrent pericarditis, expected to enter the market around 2028-2029 [6][46]. - The company is also exploring the use of Arclis in cardiac sarcoidosis, aiming to understand myocardial inflammation better through collaborations with leading medical institutions [35][36]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory of Arclis, emphasizing the importance of education and awareness in increasing prescriber confidence and patient access [19][33]. - The company remains committed to being cash flow positive annually while pursuing new indication opportunities for its pipeline products [59]. Other Important Information - The company has implemented a patient assistance program to help Medicare Part D patients afford their co-pays, which has positively impacted patient enrollment and therapy initiation [22][23]. - The company is leveraging AI and digital approaches to enhance its educational outreach to healthcare professionals and patients [20][19]. Q&A Session Summary Question: What are the growth drivers for Arclis? - The growth is driven by increased education and understanding of recurrent pericarditis among healthcare providers, leading to a broader prescriber base and higher patient enrollments [18][19]. Question: How does Medicare Part D impact patient treatment? - The changes in Medicare Part D have made therapy more affordable for patients, resulting in a one-time bolus of patients transitioning from free goods to paid therapy [22][23]. Question: What is the average treatment duration for Arclis? - The average treatment duration is reported to be 30 months, with many patients restarting therapy quickly if symptoms return [26][27]. Question: What is the strategy for KPL-387? - KPL-387 is being developed as a monthly auto-injector formulation, with strong interest from both healthcare professionals and patients, indicating a potential expansion of the market for interleukin inhibitors [40][42]. Question: What are the benefits of the Fc modified IL-1 antagonist, eleven sixty one? - The Fc modification allows for longer circulation times and potentially quarterly dosing, which could be beneficial for chronic diseases requiring long-term management [56][57].

Geoffrey MeachamManaging Director Welcome to the second day of the Citi Biopharma and Back-to-school Conference. This is our 20th annual. Last year, we didn't do it, and we opted to put all the biotech companies in the Global Healthcare Conference in Miami. And this year, we're doing both. And hopefully, you guys do both as well. So Kiniksa is with us. We're thrilled to have Sanj Patel, CEO; Ross Moat, CCO, Commercial; and John Paolini, Chief Medical Officer, [ Kiniksa ]. Thanks, guys, for joining us. The u ...

Summary of Kiniksa Pharmaceuticals International (KNSA) Conference Call Company Overview - **Company**: Kiniksa Pharmaceuticals International (KNSA) - **Key Product**: ARCALYST, a treatment for recurrent pericarditis - **Upcoming Product**: KPL-387, a potential monthly liquid formulation subcutaneous injection Core Industry Insights - **Market Penetration**: Kiniksa has achieved approximately 15% penetration into the recurrent pericarditis patient population, which consists of around 14,000 patients suffering from two or more recurrences annually [3][7] - **Sales Performance**: In Q2, Kiniksa reported net revenue of $156.8 million, reflecting a 52% year-over-year growth. The revenue guidance for the full year 2025 was raised from $590-$605 million to $625-$640 million [6][11] - **Patient Population**: The total patient population for recurrent pericarditis is estimated at 40,000, including those with first recurrences [8] Key Product Insights ARCALYST - **Compliance and Approval Rates**: Compliance for ARCALYST is over 85%, and payer approval rates exceed 90% [3][15] - **Growth Strategy**: Kiniksa is focusing on expanding its sales force and enhancing disease education to drive growth [3][4] - **Challenges**: The company faces challenges in increasing penetration due to the dispersed nature of the patient population and historical reliance on corticosteroids for treatment [12][18] KPL-387 - **Development Status**: KPL-387 is in phase two/three studies, with data expected in the second half of 2026. The product aims to provide a longer-acting treatment option [20][28] - **Market Research**: Recent market research indicates that 75% of patients would prefer KPL-387 if it meets its target profile, and 92% of healthcare professionals are likely to prescribe it [25][26] - **Transition Strategy**: Kiniksa plans to provide data to guide physicians on transitioning patients from ARCALYST to KPL-387 if approved [39] Competitive Landscape - **Market Leadership**: Kiniksa aims to maintain its leadership position in the recurrent pericarditis market despite anticipated competition [4] - **Treatment Paradigm Shift**: There is a growing recognition of the need to prioritize interleukin-1 inhibitors over corticosteroids for treating recurrent pericarditis, which aligns with Kiniksa's product offerings [13][17] Financial Performance - **Profitability**: Kiniksa has achieved cash flow breakeven and is committed to remaining cash flow positive while exploring business development opportunities [49][52] - **Investment Strategy**: The company emphasizes value creation and is open to partnerships for commercialization in regions where building infrastructure may not be feasible [53] Additional Considerations - **Global Market Opportunities**: Kiniksa is exploring opportunities outside the U.S. and considering potential partnerships for global commercialization [44][53] - **Long-term Vision**: The company is focused on innovation and maintaining leadership in therapeutic areas related to IL-1 mediated diseases [47][52] This summary encapsulates the key points discussed during the conference call, highlighting Kiniksa Pharmaceuticals' strategic direction, product performance, and market opportunities.

Market Overview - The U.S. stock market is expected to remain volatile due to uncertainty following a federal appeals court ruling that a significant portion of President Trump's worldwide tariffs is unlawful [1][7] Investment Strategy - To mitigate risks in the uncertain market, investors are advised to consider low-beta stocks such as Post Holdings, Inc. (POST), Tencent Music Entertainment Group (TME), and Kiniksa Pharmaceuticals International, plc (KNSA) [1][7] Company Insights Post Holdings - Post Holdings is restructuring its portfolio, recently announcing the divestment of its 8th Avenue pasta business for $375 million in cash, while retaining its nut butter, granola, and fruit & nut businesses for better alignment with operations and potential cost synergies [6][7] Tencent Music Entertainment - Tencent Music is poised for growth through its expanding music subscription service, boasting over 124 million paying subscribers and 15 million Super VIP members, alongside a booming advertising business supported by new ad formats and key shopping events [7][8] Kiniksa Pharmaceuticals - Kiniksa Pharmaceuticals is a leading player in treating recurrent pericarditis with its drug ARCALYST, which is currently the only treatment option available for this condition [9][7]

Shares of Kiniksa Pharmaceuticals International, plc (KNSA) have gained 15% over the past four weeks to close the last trading session at $33.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $42.29 indicates a potential upside of 26.7%. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issue ...

Core Viewpoint - The sustainability of a trend is crucial for successful short-term investing, and confirming fundamental factors is essential to maintain momentum in stocks [1][2]. Group 1: Trend Analysis - Timing entries into a trend significantly impacts investment success, as trends can reverse unexpectedly, leading to potential losses [1][2]. - A predefined screening strategy, "Recent Price Strength," helps identify stocks with strong fundamentals that can sustain their upward trends [3]. Group 2: Company Spotlight - Kiniksa Pharmaceuticals International, plc (KNSA) - KNSA has shown a solid price increase of 24.1% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also increased by 15% in the last four weeks, suggesting that the upward trend is still intact [5]. - KNSA is trading at 96.3% of its 52-week high-low range, indicating a potential breakout [5]. Group 3: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, underscoring the effectiveness of this ranking system [7]. Group 4: Investment Opportunities - In addition to KNSA, there are other stocks that meet the criteria of the "Recent Price Strength" screen, providing additional investment opportunities [8]. - The Zacks Premium Screens offer over 45 strategically created options to help investors find winning stock picks based on their personal investing styles [8].

Market Overview - U.S. stock markets have continued to rise in early August despite trade uncertainties and the Federal Reserve's indecision regarding interest rate cuts in 2025 [1][2] - The outcome of the Fed's annual Jackson Hole Symposium, scheduled for August 21-23, is anticipated to be significant [2] Stock Performance - Few stocks have demonstrated price strength, with a focus on those recently experiencing a bull run [3] - Five highlighted stocks include Modine Manufacturing Co. (MOD), Tutor Perini Corp. (TPC), Kiniksa Pharmaceuticals International plc (KNSA), Life360 Inc. (LIF), and Euroseas Ltd. (ESEA) [3] Stock Screening Criteria - Stocks must show a percentage change in price greater than zero over the last four weeks and greater than 10% over the last twelve weeks [5] - Zacks Rank 1 (Strong Buy) and an average broker rating of 1 are also key indicators of potential performance [6] - Stocks must be trading at a minimum price of $5 and be near their 52-week highs, with a current price/52-week high-low range greater than 85% [7] Individual Stock Highlights - **Modine Manufacturing (MOD)**: Stock price increased by 46.1% in four weeks, with an expected earnings growth rate of 14.3% for the current year [8][10] - **Tutor Perini (TPC)**: Stock price surged 14.3% in four weeks, with an expected earnings growth rate exceeding 100% for the current year [14] - **Kiniksa Pharmaceuticals (KNSA)**: Stock price climbed 13.7% in four weeks, with expected earnings growth over 100% for the current year [15] - **Life360 (LIF)**: Stock price advanced 8.3% in four weeks, with expected earnings growth over 100% for the current year [17] - **Euroseas (ESEA)**: Stock price gained 2.8% in four weeks, with an expected earnings growth rate of 4% for the current year [19]

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Kiniksa Pharmaceuticals International, plc currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Set to Beat the Market? Moment ...

Core Viewpoint - Kiniksa Pharmaceuticals International, plc (KNSA) is experiencing solid improvements in earnings estimates, which may lead to continued short-term price momentum and a favorable investment opportunity [1][10]. Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism regarding Kiniksa's earnings prospects, which is expected to positively influence its stock price [2]. - The current-quarter earnings estimate of $0.29 per share indicates a significant increase of +261.1% compared to the previous year, with a 36.51% rise in the Zacks Consensus Estimate over the last 30 days due to two upward revisions [5][6]. - For the full year, Kiniksa is projected to earn $0.94 per share, representing a +256.7% change from the prior year, with a 26.58% increase in the consensus estimate over the past month [6][7]. Zacks Rank - Kiniksa currently holds a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on favorable estimate revisions [8]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting a robust track record of success [3][9]. Stock Performance - The stock has gained 8.5% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects, making it a candidate for portfolio consideration [10].